Search Within

Renier J Brentjens

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Meeting Abstract (79)
  2. Journal Article (49)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Adult Leukemia (130)
  2. Center for Hematologic Malignancies (130)
  3. Department of Medicine (130)
  4. GSK Faculty (130)
  5. Hematologic Malignancies Research (130)
  6. Hematologic Malignancies, Division of (130)

More Groups

People
  1. Michel Sadelain (116)
  2. Isabelle Riviere (99)
  3. Jae Park (68)
  4. Xiuyan Wang (56)
  5. Kevin Curran (32)
  6. Elizabeth Halton (28)

More People

Years
  1. 2023 (2)
  2. 2022 (4)
  3. 2021 (6)
  4. 2020 (5)
  5. 2019 (10)
  6. 2018 (10)

More Years

Publications
  1. Blood (39)
  2. Journal of Clinical Oncology (17)
  3. Molecular Therapy (14)
  4. Cancer Research (6)
  5. Haematologica (5)
  6. Nature Medicine (5)

More Publications

Publishers
  1. American Society of Hematology (40)
  2. Nature Publishing Group (28)
  3. American Society of Clinical Oncology (18)
  4. American Association for Cancer Research (10)
  5. Elsevier Inc. (7)
  6. Ferrata Storti Foundation (5)

More Publishers

Results (130)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Graded potency of chimeric antigen receptor (CAR)-engineered T cells for cancer immunotherapy
    Meeting Abstract

    Sadelain, M.; Condomines, M.; Zhao, Z.; Brentjens, R. J.; Riviere, I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I trial of autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bartido, S.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    Meeting Abstract

    Sadelain, M.; Brentjens, R.; Davila, M.; Riviere, I.; Wang, X. Y.; Bartido, S.; Park, J.; Bouhassira, D.; Curran, K.; Chung, S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y. J.; Wang, X. Y.; Purdon, T. J.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Engineered T cell receptor-mimic antibody, (TCRm) chimeric antigen receptor (CAR) T cells against the intracellular protein Wilms tumor-1 (WT1) for treatment of hematologic and solid cancers
    Meeting Abstract

    Rafiq, S.; Dao, T.; Liu, C.; Scheinberg, D. A.; Brentjens, R. J.
    Blood (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen for the treatment of pediatric relapsed B cell ALL
    Meeting Abstract

    Curran, K. J.; Riviere, I.; Kobos, R.; Kernan, N. A.; Boulad, F.; Prockop, S. E.; Scaradavou, A.; Renaud, T. M.; Shukla, N.; Steinherz, P. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • The Warburg effect confers adverse outcome in chronic lymphocytic leukemia
    Meeting Abstract

    Gardner, J. R.; Devlin, S. M.; Knapp, K.; Bauli, F.; Patel, M.; Lamanna, N.; Frattini, M. G.; Brentjens, R.; Maslak, P.; Jurcic, J. G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2014)

    Fulltext@MSK | Save
  • Phase I trial of autologous Cd19-targeted car-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated cll
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Bartido, S.; Sadelain, M.; Brentjens, R. J.
    Haematologica (2014)

    Fulltext@MSK | Save